1. Health Canada approves Ventripoint’s complete heart analysis system for 2D ultrasounds
Ventripoint Diagnostics received a license from Health Canada for its new VMS-Plus machine and the 4-chamber (4C) heart analysis system, according to a March 2 news release. It was already licensed to use with the right ventricle and is now licensed to analyze the right atrium, left atrium and left ventricle. The volume and function for all 4 chambers will be better recognized with conventional 2D ultrasounds, as compared to the previous MRI method.
2. RenalGuard touts clinical study
RenalGuard Therapy’s new study shows that its RenalGuard System has the potential to prevent cardiac contrast-agent inducing acute kidney injury (CI-AKI) in high-risk patients who are undergoing percutaneous coronary interventions or trans catheter aortic valve replacements, according to a Feb. 28 news release. The report showed that the RenalGuard System had a significant reduction of CI-AKI, lowered the need for patient dialysis and a positive trend of lower mortality rates post-procedure. It also reduced the frequency of post-procedural acute coronary syndrome, stroke and acute pulmonary edema. Patients treated with the system also had a high urine output, even though they had severely depressed kidney function, and had no significant changes in electrolyte balance.
3. NeuroVision participates in Alzheimer’s study
NeuroVision Imaging announced that it is participating in a new anti-amyloid treatment in asymptomatic Alzheimer’s (A4) substudy and clinical trial with the University of California San Diego School of Medicine and the University of Southern California, according to a Feb. 27 news release. The A4 study tests a new investigational treatment that may reduce beta-amyloid accumulation in the brain. The goal is to determine whether the treatment slows memory loss from Alzheimer’s. NeuroVision’s retinal imaging technology will help characterize retinal amyloid imaging findings in patients who have preclinical Alzheimer’s disease. The patients will receive treatment as part of the A4 study. The substudy also intends to assess longitudinal changes in retinal amyloid imaging with Alzheimer’s patients.